Compare, Analyse Dishman Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MYLAN (US) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   MYLAN
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MYLAN
Dec-18
DISHMAN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3743,570-   
Low Rs1291,965-   
Sales per share (Unadj.) Rs197.81,642.9-  
Earnings per share (Unadj.) Rs21.244.6-  
Cash flow per share (Unadj.) Rs34.7352.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.91,777.4-  
Shares outstanding (eoy) m80.69514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 75.5%   
Avg P/E ratio x11.962.0 19.1%  
P/CF ratio (eoy) x7.27.9 92.2%  
Price / Book Value ratio x1.41.6 89.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3061,424,069 1.4%   
No. of employees `0000.835.0 2.4%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.724,151.1 79.7%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1655.8 314.7%   
INCOME DATA
Net Sales Rs m15,961845,288 1.9%  
Other income Rs m2650-   
Total revenues Rs m16,226845,288 1.9%   
Gross profit Rs m4,103218,729 1.9%  
Depreciation Rs m1,091158,271 0.7%   
Interest Rs m94440,655 2.3%   
Profit before tax Rs m2,33419,803 11.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-3,150 -19.8%   
Profit after tax Rs m1,71122,953 7.5%  
Gross profit margin %25.725.9 99.4%  
Effective tax rate %26.7-15.9 -168.0%   
Net profit margin %10.72.7 394.8%  
BALANCE SHEET DATA
Current assets Rs m11,018472,008 2.3%   
Current liabilities Rs m9,517344,146 2.8%   
Net working cap to sales %9.415.1 62.2%  
Current ratio x1.21.4 84.4%  
Inventory Days Days11084 132.2%  
Debtors Days Days3593 37.3%  
Net fixed assets Rs m16,304163,972 9.9%   
Share capital Rs m161450 35.9%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,516914,447 1.6%   
Long term debt Rs m4,189986,982 0.4%   
Total assets Rs m29,8052,452,902 1.2%  
Interest coverage x3.51.5 233.4%   
Debt to equity ratio x0.31.1 26.7%  
Sales to assets ratio x0.50.3 155.4%   
Return on assets %8.92.6 343.6%  
Return on equity %11.82.5 469.6%  
Return on capital %17.53.2 551.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786175,651 1.6%  
From Investments Rs m-1,529-90,792 1.7%  
From Financial Activity Rs m-941-81,828 1.2%  
Net Cashflow Rs m3161,455 21.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 75.01 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: SANOFI INDIA  FRESENIUS KABI ONCO.  ALKEM LABORATORIES  FULFORD INDIA  NEULAND LABS  



Today's Market

Sensex Opens Marginally Higher; Infosys Dips 4% Post Q4 Results(09:30 am)

Asian share markets are trading on a negative note today following mixed cues from Wall Street.

Related Views On News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday (Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS